TECH Bio-Techne Corporation
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.
Company profile
Ticker
TECH
Exchange
Website
CEO
Charles R. Kummeth
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • Gilead Sciences • Biogen • QIAGEN • Moderna • BioNTech SE • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...
Former names
TECHNE CORP /MN/
SEC CIK
Corporate docs
IRS number
411427402
TECH stock data
()
Calendar
26 Aug 20
24 Sep 20
30 Jun 21
News
Financial summary
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jun 20 | Jun 19 | Jun 18 | Jun 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Bio-Techne earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 9 Aug 20 | Hippel James | Common Stock | Payment of exercise | Dispose F | No | 265.76 | 2,184 | 580.42K | 9,137 |
| 9 Aug 20 | Hippel James | Common Stock | Option exercise | Aquire M | No | 0 | 4,438 | 0 | 11,321 |
| 9 Aug 20 | Hippel James | RSU Common Stock | Option exercise | Dispose M | No | 0 | 4,438 | 0 | 0 |
| 9 Aug 20 | Kummeth Charles R. | Common Stock | Payment of exercise | Dispose F | No | 265.76 | 12,287 | 3.27M | 161,487 |
| 9 Aug 20 | Kummeth Charles R. | Common Stock | Option exercise | Aquire M | No | 0 | 21,291 | 0 | 173,774 |
| 9 Aug 20 | Kummeth Charles R. | RSU Common Stock | Option exercise | Dispose M | No | 0 | 21,291 | 0 | 0 |
| 9 Aug 20 | Furlow Brenda S. | Common Stock | Payment of exercise | Dispose F | No | 265.76 | 849 | 225.63K | 5,186 |
| 9 Aug 20 | Furlow Brenda S. | Common Stock | Option exercise | Aquire M | No | 0 | 1,724 | 0 | 6,035 |
| 9 Aug 20 | Furlow Brenda S. | RSU Common Stock | Option exercise | Dispose M | No | 0 | 1,724 | 0 | 0 |
| 9 Aug 20 | Norman David Eansor | Common Stock | Payment of exercise | Dispose F | No | 265.76 | 856 | 227.49K | 1,318 |
Institutional ownership Q2 2020
0.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 12K |
| Total shares | 46 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Gemmer Asset Management | 26 | $7K |
| Tower View Investment Management & Research | 20 | $5K |
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
abide, accrual, acqusition, adhere, bargaining, bioprocessing, breakdown, brought, CCPA, CDC, certainty, cgmp, chain, closure, commencement, conditionality, conference, Cosmetic, death, dedesignated, distancing, eased, economy, effort, encouraged, EPS, exit, facilitate, Facilitation, factual, fall, FDCA, GDPR, great, half, hindsight, home, Hospital, hygiene, implicit, interacting, IVDR, Kabi, Kantaro, kit, labeling, lessee, malfunction, malfunctioned, MDR, member, Mount, moving, NaN, Noncurrent, notice, onset, outlook, pandemic, Paul, penalty, pervasive, prolonged, prompt, prompted, Prosate, QSR, Quickgel, rapid, reaction, recommended, recovery, relieved, resurgence, Saint, scrutiny, serology, short, Sinai, specialty, staggered, summer, supervisory, surveillance, sweeping, TcBuster, Terminology, thereof, thereto, transmit, travel, unapproved, uninterrupted, vaccine, Wilson, Wolf
Removed:
adjacent, bolster, build, committed, community, detailed, determinable, drove, easier, epic, equal, exceed, executing, experiencing, forma, GE, grew, implicating, incidental, informational, innovative, integrating, Italian, Italy, membership, met, Milan, monitoring, municipal, noted, November, opposed, Ottawa, owed, partner, pooled, pro, purpose, recruit, remediated, reportable, sound, Srl, strive, sufficiency, summarized, talented, tied, train, transact, unvested
Financial reports
10-K
2020 FY
Annual report
26 Aug 20
10-Q
2020 Q3
Quarterly report
11 May 20
10-Q
2020 Q2
Quarterly report
6 Feb 20
10-Q
2020 Q1
Quarterly report
6 Nov 19
10-K/A
2019 FY
Annual report (amended)
6 Nov 19
10-K/A
2019 FY
Annual report (amended)
9 Oct 19
10-K
2019 FY
Annual report
28 Aug 19
10-Q
2019 Q3
Quarterly report
7 May 19
10-Q
2019 Q2
Quarterly report
7 Feb 19
10-Q
2019 Q1
Quarterly report
7 Nov 18
Current reports
8-K
Bio-techne Releases Fourth Quarter Fiscal 2020 Results
4 Aug 20
8-K
Bio-techne and Kantaro Biosciences Announce Partnership to Develop and Scale Production of COVID-19 Serology Test
19 May 20
8-K
Bio-techne Releases Third Quarter Fiscal 2020 Results
30 Apr 20
8-K
Bio-techne Releases Second Quarter Fiscal 2020 Results
4 Feb 20
8-K
Bio-techne Releases First Quarter Fiscal 2020 Results
29 Oct 19
8-K
Bio-techne Releases Fourth Quarter Fiscal 2019 Results
6 Aug 19
8-K
Bio-Techne Appoints Rupert Vessey to Board of Directors
25 Jun 19
8-K
Bio-techne Releases Third Quarter Fiscal 2019 Results
30 Apr 19
8-K
Bio-techne Releases Second Quarter Fiscal 2019 Results
5 Feb 19
8-K
Bio-techne Releases First Quarter Fiscal 2019 Results
30 Oct 18
Registration and prospectus
S-8
Registration of securities for employees
7 Nov 18
S-8
Registration of securities for employees
26 Oct 17
S-8
Registration of securities for employees
30 Oct 15
S-8
Registration of securities for employees
4 Nov 14
S-8
Registration of securities for employees
12 Nov 10
S-8
Registration of securities for employees
15 Nov 00
S-8
Registration of securities for employees
13 Oct 99
S-3
Shelf registration
1 Oct 98
S-8
Registration of securities for employees
6 Oct 97
S-8
Registration of securities for employees
16 Oct 96
Proxies
DEFA14A
Additional proxy soliciting materials
15 Sep 20
DEF 14A
Definitive proxy
15 Sep 20
DEFA14A
Additional proxy soliciting materials
9 Sep 19
DEF 14A
Definitive proxy
9 Sep 19
DEF 14A
Definitive proxy
11 Sep 18
DEFA14A
Additional proxy soliciting materials
11 Sep 18
DEF 14A
Definitive proxy
12 Sep 17
DEFA14A
Additional proxy soliciting materials
12 Sep 17
DEF 14A
Definitive proxy
13 Sep 16
DEFA14A
Additional proxy soliciting materials
13 Sep 16
Other
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
29 May 19
SD
Conflict minerals disclosure
25 May 18
UPLOAD
Letter from SEC
1 May 18
CORRESP
Correspondence with SEC
5 Apr 18
SD
Conflict minerals disclosure
26 May 17
UPLOAD
Letter from SEC
16 May 17
CORRESP
Correspondence with SEC
5 May 17
UPLOAD
Letter from SEC
21 Apr 17
CORRESP
Correspondence with SEC
23 Mar 17
Ownership
4
BIO-TECHNE / Brenda S. Furlow ownership change
11 Aug 20
4
BIO-TECHNE / Norman David Eansor ownership change
11 Aug 20
4
BIO-TECHNE / James Hippel ownership change
11 Aug 20
4
BIO-TECHNE / Charles R. Kummeth ownership change
11 Aug 20
4
BIO-TECHNE / Charles R. Kummeth ownership change
7 Aug 20
4
BIO-TECHNE / Kim Kelderman ownership change
7 Aug 20
4
BIO-TECHNE / James Hippel ownership change
7 Aug 20
4
BIO-TECHNE / Brenda S. Furlow ownership change
7 Aug 20
4
BIO-TECHNE / Norman David Eansor ownership change
7 Aug 20
4
BIO-TECHNE / Julie L Bushman ownership change
5 Aug 20
Patents
GRANT
Utility
Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
25 Aug 20
Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
GRANT
Utility
Dual chamber storage device
5 May 20
A dual chamber storage device includes a first chamber having a base and a hollow body for storing a first material.
GRANT
Utility
Dual chamber storage device
5 May 20
A dual chamber storage device includes a first chamber having a base and a hollow body for storing a first material.
APP
Utility
IL-37 Fusion Protein and Methods of Making and Using Same
20 Feb 20
The disclosure provides interleukin 37 (IL-37) fusion proteins, methods of making IL-37 fusion proteins including constructs used to express IL-37 fusion proteins, and methods of using IL-37 fusion proteins.
APP
Utility
Dual Chamber Storage Device
21 Nov 19
A dual chamber storage device includes a first chamber having a base and a hollow body for storing a first material.